Stockscreener 앱 받기
561.55
0.90%
4.995
시간 외 거래:
560.00
-1.55
-0.28%
전일 마감가:
$556.55
열려 있는:
$557.08
하루 거래량:
1.10M
Relative Volume:
0.92
시가총액:
$58.50B
수익:
$14.21B
순이익/손실:
$4.46B
주가수익비율:
14.15
EPS:
39.68
순현금흐름:
$3.56B
1주 성능:
+1.16%
1개월 성능:
-1.09%
6개월 성능:
-16.72%
1년 성능:
-51.52%
1일 변동 폭
$552.00
$565.50
1주일 범위
$544.16
$572.58
52주 변동 폭
$476.49
$1,211.20
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Fund Update: DODGE & COX added 1,502,198 shares of REGENERON PHARMACEUTICALS (REGN) to their portfolio - Quiver Quantitative
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game-Changer? - TipRanks
Cantor Fitzgerald maintains Regeneron stock rating despite mixed update By Investing.com - Investing.com Canada
Here’s Why You Should Consider Buying Regeneron Pharma (REGN)’s Shares - Insider Monkey
Lead Plaintiff Appointed in Regeneron Pharmaceuticals Class Action - TradingView
Charles Schwab Investment Management Inc. Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Citizens Financial Group Inc. RI Sells 465 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Mizuho Securities USA LLC - MarketBeat
National Bank of Canada FI Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Deutsche Bank AG Has $344.45 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Forsta AP Fonden Sells 1,300 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Maryland State Retirement & Pension System Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Townsquare Capital LLC Purchases 2,854 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Swiss National Bank - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know - FinancialContent
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00 - MarketBeat
Sanofi halts China sales of cholesterol drug Praluent (SNY) - Seeking Alpha
Guggenheim Lifts PT on Regeneron Pharmaceuticals (REGN) to $815 From $810 - MSN
Knott David M Jr Takes $1.27 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Invesco Ltd. Has $539.57 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
AIA Group Ltd Boosts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sanofi stops supply of high cholesterol drug to China due to limited availability - The Mighty 790 KFGO
Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners - MSN
Nuveen LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Cary Street Partners Financial LLC Sells 959 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
ASR Vermogensbeheer N.V. Buys Shares of 9,485 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Headlands Technologies LLC Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity (NASDAQ:REGN) - Seeking Alpha
This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point - Stocktwits
Truist Securities lowers Regeneron Pharma stock price target on Eylea concerns - Investing.com
A Look Into Regeneron Pharmaceuticals Inc's Price Over Earnings - Benzinga
Follicular Lymphoma Market Trends Point to Steady Growth Ahead - openPR.com
Follicular Lymphoma Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Roche, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly - Barchart.com
Truist Securities Adjusts Regeneron Pharmaceuticals Price Target to $812 From $940, Maintains Buy Rating - MarketScreener
Zymeworks Strengthens Board with Healthcare Veterans as Key Trial Results Near - Stock Titan
Aigen Investment Management LP Decreases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Entropy Technologies LP - MarketBeat
What Regeneron Pharmaceuticals (REGN)'s Strong Q2 Results and Dupixent FDA Approval Mean For Shareholders - simplywall.st
Cornerstone Advisors LLC Has $3.87 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
BMO Capital Lifts PT on Regeneron Pharmaceuticals (REGN) Stock, Keeps Outperform - MSN
New Age Alpha Advisors LLC Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
11 Best GLP-1 and Weight Loss Stocks to Invest in - Insider Monkey
Goldman Sachs Group Inc. Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.60%
자본화:
|
볼륨(24시간):